Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Directly age-standardised registration rate for oral cancer (ICD-10 C00-C14), in persons of all ages, per 100,000 2013 European Standard PopulationRationaleTobacco is a known risk factor for oral cancers (1). In England, 65% of hospital admissions (2014–15) for oral cancer and 64 % of deaths (2014) due to oral cancer were attributed to smoking (2). Oral cancer registration is therefore a direct measure of smoking-related harm. Given the high proportion of these registrations that are due to smoking, a reduction in the prevalence of smoking would reduce the incidence of oral cancer.Towards a Smokefree Generation: A Tobacco Control Plan for England states that tobacco use remains one of our most significant public health challenges and that smoking is the single biggest cause of inequalities in death rates between the richest and poorest in our communities (3).In January 2012 the Public Health Outcomes Framework was published, then updated in 2016. Smoking and smoking related death plays a key role in two of the four domains: Health Improvement and Preventing premature mortality (4).References:(1) GBD 2013 Risk Factors Collaborators. Global, regional and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk factors in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015; 386:10010 2287–2323. (2) Statistics on smoking, England 2016, May 2016; http://content.digital.nhs.uk/catalogue/PUB20781 (3) Towards a Smokefree Generation: A Tobacco Control Plan for England, July 2017 https://www.gov.uk/government/publications/towards-a-smoke-free-generation-tobacco-control-plan-for-england (4) Public Health Outcomes Framework 2016 to 2019, August 2016; https://www.gov.uk/government/publications/public-health-outcomes-framework-2016-to-2019 Definition of numeratorCancer registrations for oral cancer (ICD-10, C00-C14) in the calendar years 2007-09 to 2017-2019. The National Cancer Registration and Analysis Service collects data relating to each new diagnosis of cancer that occurs in England. This does not include secondary cancers. Data are reported according to the calendar year in which the cancer was diagnosed.Definition of denominatorPopulation-years (ONS mid-year population estimates aggregated for the respective years) for people of all ages, aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+).CaveatsReviews of the quality of UK cancer registry data 1, 2 have concluded that registrations are largely complete, accurate and reliable. The data on cancer registration ‘quality indicators’ (mortality to incidence ratios, zero survival cases and unspecified site) demonstrate that although there is some variability, overall ascertainment and reliability is good. However cancer registrations are continuously being updated, so the number of registrations for each year may not be complete, as there is a small but steady stream of late registrations, some of which only come to light through death certification.1. Huggett C (1995). Review of the Quality and Comparability of Data held by Regional Cancer Registries. Bristol: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry. 2. Seddon DJ, Williams EMI (1997). Data quality in population based cancer registration. British Journal of Cancer 76: 667-674.The data presented here replace versions previously published. Population data and the European Standard Population have been revised. ONS have provided an explanation of the change in standard population (available at http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html )

The English Cancer Patient Experience Survey (CPES) is commissioned by NHS England and administered on their behalf by an external survey provider organisation (Quality Health). The survey provides insights into the care experienced by cancer patients across England who were treated as day cases or inpatients. Data from CPES has been linked to cancer registration records recorded by the National Cancer Registration and Analysis Service (the cancer registry in England). Individual responses to Wave 2 of CPES are recorded , alongside characteristics of the patient who has completed the survey. Wave 2 of the National Cancer Patient Experience Survey is limited to patients discharged from cancer care between 01/09/2011 – 30/11/2011. Data within the file: --PATIENT_PSEUDO_ID (Project specific Pseudonymised Patient ID) GENDER (coded Male, Female) --QUINTILE2010 (Deprivation quintile [1-5], describing the Income Deprivation Domain where 1= least deprived and 5= most deprived) --FINAL_ROUTE (One of eight Routes to Diagnosis- methodology for the assignment of each route is described in Elliss-Brookes L, McPhail S, Greenslade M, Shelton J, Hiom S, Richards M (2012) Routes to diagnosis for cancer – determining the patient journey using multiple routine data sets. British Journal of Cancer 107: 1220–1226.) --AGE (aggregated in 4 categories: <55, 55-64, 65-74, 75+) --STAGE (stage of the cancer coded as I, II, III, IV, missing) --CANCER_SITE (Cancer sites coded in accordance with ICD 10: C00-C14, C15, C16, C18, C19-C20, C25, C33-C34, C43, C49, C50, C54, C56, C61, C64, C67, C73, C82, C83, C85, C90, C91-C95, D05 and ‘all other ICD-10 codes’ Specific disclosure controls applied: --Gender omitted from the data specification in the following cancer sites: • Female only for C50, D05 and C73 • Male only for C49 --Self-reported ethnicity (from the CPES surveys) aggregated into white British / non-white British / not specified. --Self-reported ethnicity omitted for C49, C64, C73 (replaced as “missing”).

This is a names and codes file for cancer registries in England and Wales as at 1 January 2009. (File Size - 1 KB)

Rapid Cancer Registration Data (RCRD) provides a quick, indicative source of cancer data. It is provided to support the planning and provision of cancer services. The data is based on a rapid processing of cancer registration data sources, in particular on Cancer Outcomes and Services Dataset (COSD) information. In comparison, National Cancer Registration Data (NCRD) relies on additional data sources, enhanced follow-up with trusts and expert processing by cancer registration officers. The Rapid Cancer Registration Data (RCRD) may be useful for service improvement projects including healthcare planning and prioritisation. However, it is poorly suited for epidemiological research due to limitations in the data quality and completeness.

The National Cancer Registration and Analysis Service (NCRAS) at Public Health England supplies cancer registration data to NHS Digital. This data is available to be linked to other data held by NHS Digital in order to provide notifications on an individual's cancer status, be available to support research studies and to identify potential research participants for clinical trials.

NCRAS is the population-based cancer registry for England. It collects, quality assures and analyses data on all people living in England who are diagnosed with malignant and pre-malignant neoplasms, with national coverage since 1971.

The Cancer Registration dataset comprises England data to the present day, and Welsh data up to April 2017.

Timescales for dissemination of agreed data can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process Standard response

BCR was established on 28 June 2005 in a partnership between the federal and regional Belgian governments. The registry collects information about all new cancer diagnoses in Belgium. Based on this information, it securely processes cancer data in the context of the nature and extent of cancer and cancer care. BCR works closely with the various Belgian centres that diagnose cancers, particularly hospitals and pathological anatomy/clinical biology/haematology laboratories.

BackgroundColorectal cancer incidence in the UK and other high-income countries has been increasing rapidly among young adults. This is the first analysis of colorectal cancer incidence trends by sub-site and socioeconomic deprivation in young adults in a European country.MethodsWe examined age-specific national trends in colorectal cancer incidence among all adults (20–99 years) diagnosed during 1971–2014, using Joinpoint regression to analyse data from the population-based cancer registry for England. We fitted a generalised linear model to the incidence rates, with a maximum of two knots. We present the annual percentage change in incidence rates in up to three successive calendar periods, by sex, age, deprivation and anatomical sub-site.ResultsAnnual incidence rates among the youngest adults (20–39 years) fell slightly between 1971 and the early 1990s, but increased rapidly from then onwards. Incidence Rates (IR) among adults 20–29 years rose from 0.8 per 100,000 in 1993 to 2.8 per 100,000 in 2014, an average annual increase of 8%. An annual increase of 8.1% was observed for adults aged 30–39 years during 2005–2014. Among the two youngest age groups (20–39 years), the average annual increase for the right colon was 5.2% between 1991 and 2010, rising to 19.4% per year between 2010 (IR = 1.2) and 2014 (IR = 2.5). The large increase in incidence rates for cancers of the right colon since 2010 were more marked among the most affluent young adults. Smaller but substantial increases were observed for cancers of the left colon and rectum. Incidence rates in those aged 50 years and older remained stable or decreased over the same periods.ConclusionsDespite the overall stabilising trend of colorectal cancer incidence in England, incidence rates have increased rapidly among young adults (aged 20–39 years). Changes in the prevalence of obesity and other risk factors may have affected the young population but more research is needed on the cause of the observed birth cohort effect. Extension of mass screening may not be justifiable due to the low number of newly diagnosed cases but clinicians should be alert to this trend.

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is valued to increase USD 121.9 million, at a CAGR of 14% from 2024 to 2029. The growing prevalence of cancer cases will drive the cancer registry software market.

Major Market Trends & Insights

North America dominated the market and accounted for a 51% growth during the forecast period.
By End-user - Government and third party segment was valued at USD 24.20 million in 2023
By Type - Stand-alone software segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: 181.04 million
Market Future Opportunities: USD 121.90 million
CAGR : 14%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape shaped by advancements in core technologies and applications, service types, and regulatory frameworks. With the growing prevalence of cancer cases worldwide, the demand for robust and efficient cancer registry software solutions has surged. The growth is fueled by the increasing clinical research for oncology and the need for accurate, standardized data collection and analysis.
However, data privacy and security concerns pose significant challenges, necessitating stringent compliance with regulations such as HIPAA and GDPR. As regional healthcare systems adopt digital transformation, the market is witnessing a proliferation of solutions tailored to specific needs in North America, Europe, and Asia Pacific.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Registry Software Market Segmented and what are the key trends of market segmentation?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premises
  Cloud-based


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.

Cancer registry software plays a pivotal role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These solutions facilitate the collection, storage, and statistical modeling of oncology data, enabling agencies to monitor cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. Governments utilize cancer registry software to ensure data quality through data validation rules, de-identification, and HIPAA compliance. They also employ data visualization tools, reporting dashboards, and data integration methods to analyze trends and patterns. This data analysis helps identify high-risk populations, geographic disparities, and emerging cancer types.

Moreover, cancer registry software supports population health management and patient data management, ensuring secure data storage, user access control, and audit trails. API integrations enable seamless data exchange with other healthcare systems, facilitating clinical data exchange and follow-up procedures. The future of cancer registry software is promising, with adoption expected to grow significantly. According to recent studies, the number of cancer registries worldwide is projected to increase by 20%, while the use of electronic registries is anticipated to surge by 30%. These trends reflect the ongoing digitization of healthcare and the growing recognition of the value of data-driven insights in improving cancer care and outcomes.

Request Free Sample

The Government and third party segment was valued at USD 24.20 million in 2019 and showed a gradual increase during the forecast period.

Furthermore, cancer registry software supports cancer surveillance, disease registries, and cancer staging, providing valuable data for mortality reporting and treatment protocols. It also facilitates incidence reporting, case ascertainment, and survival analysis, ensuring that governments and third-party agencies have access to the most accurate and up-to-date information for informed decision-making. In conclusion, cancer registry software is a crucial tool for governments and third-party agencies seeking to monitor and improve cancer care. Its features, including

Odds ratios (95% confidence intervals) from multinomial multivariable logistic regression comparing sources of palliative care, compared with no palliative care, by patient characteristics.

Demographic characteristics by palliative care provision.

Genomics England are striving to improve the clinical data provided for its researchers. We understand the value of accurate and granular clinical data, especially in the context of cancer.

In order to deliver this, we are planning a series of pilot datasets, aiming to incorporate additional clinical data provided by Public Health England cancer registry (NCRAS). Genomics England will aim to deliver cancer specific datasets, with the initial focus being on providing a broad pathological understanding. This will aim to incorporate data points such as molecular mutations and resection margins in pathology reports. The focus will then incorporate radiological imaging reports and finally focus on live/ up-to-date clinical data. In addition, we are also including the date each participant was last seen alive (data provided up to October 2020) and dates and causes of death to aid with outcomes.

It must be stressed that this work is a development process, and we are working in unison with NCRAS to progress this. Whilst we do not possess the extensive experience and resource of Public Health England, we are developing a natural language based algorithm for focused data extraction. NCRAS have a dedicated team to curating clinical data and the gold standard remains the NCRAS curated tables. However, for this dataset to improve and move forward, Genomics England are keen for feedback and for you to highlight areas for improvement.

You will note subtle differences to the structure of the table compared to the curated NCRAS tables and thus additional data dictionaries have been provided. Genomics England hopes to continue developing this uncurated live dataset with feedback and look forward to hearing your thoughts. Please reach out to us with related thoughts and suggestions via the Genomics England Service Desk, including "cancer_specific_datasets_pilot" in the title of your enquiry.

With the addition of the new pathology_reports dataset introduced in v16, the aml_path_reports and testes_path_reports datasets have been deprecated in v17.

Therapies received by palliative care provision.

Type and duration of cancer by palliative care provision.

Cancer registrations for Breast cancer per 100,000 population. Directly standardised registration rate Source: Regional Cancer Registries, Office for National Statistics (ONS). Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2004-2006 Type of data: Administrative data

This report presents trends in cancer incidence and survival updated with incidence and mortality . Source agency: Cancer Registry Northern Ireland Designation: Official Statistics not designated as National Statistics Language: English Alternative title: Cancer Incidence and Survival Trends in Northern Ireland

National Cancer Registration and Analysis Service (NCRAS). (2019). Cancer Registration: Epidemiology of Melanoma (1995-2017) [Dataset]. Public Health England. https://doi.org/10.25503/n202-3352

Each row represents a C43* tumour. For each tumour the following is provided where available:

• BRESLOW, (Breslow thickness of tumour, Measured in millimetres to the nearest 0.01mm. Can be a number or range, x, or blank (e.g. ≤1mm, 1-2mm)

• diag_quarter (diagnosis quarter is based on the calendar year)

• DIAGNOSISYEAR, (year of diagnosis, 1995-2017)

• ethnicity_band (aggregated in 3 categories: 'White'; 'Non-White' and 'Unknown')

• age_group (aggregated in 3 categories: '<45'; '45-69' and '70+')

• HISTOLOGY_CODED, (histology code - combines the morphology and behaviour codes)

• HISTOLOGY_CODED_DESC, (name for the histology type)

• SEX, (coded as 1=Male and 2=Female)

• SITE_ICD10_O2, (valid 4-digit code, coded in accordance with classification system of The International Classification of Diseases for Oncology) (C430-C439)

• SITE_CODED_DESC, (Site code of the cancer, in the coding system that the tumour was originally coded in and text description)

• T_IMG, (The UICC code which classifies the size and extent of the primary tumour before treatment)

• N_IMG, (The UICC code which classifies the absence or presence and extent of regional lymph node metastases before treatment. +, 0, 1, 1a, 1b, 1c, 1mi, 2, 2a, 2b, 2c, 3, 3a, 3b, 3c, X)

• M_IMG, The UICC code which classifies the absence or presence of distant metastases pre-treatment. 0 = no distant metastasis. 1, 1a, 1b, 1c, 1e = distant metastasis. X = unknown)

• CREG_CODE, (Cancer registry catchment area code (at diagnosis) Y0201 = Northern and Yorkshire Cancer Registry and Information Service; Y0301 = Trent Cancer Registry; Y0401 = Eastern Cancer Registration and Information Centre; Y0801 = Thames Cancer Registry; Y0901 = Oxford Cancer Intelligence Unit; Y1001 = South West Cancer Intelligence Service; Y1101 = Welsh Cancer Intelligence and Surveillance Unit; Y1201 = West Midlands Cancer Intelligence Unit; Y1701 = North West Cancer Intelligence Service; Z9999 = null.

• CREG_NAME, Cancer registry catchment area name (at diagnosis) See above for coding.

• BASISOFDIAGNOSIS, Basis of diagnosis of the tumour according to all the data received by the registry. Non-microscopic: 0 = Death certificate; 1 = Clinical: Diagnosis made before death without (2-7); 2 = Clinical investigation: Includes all diagnostic techniques without a tissue diagnosis; 4 = Specific tumour markers: Includes biochemical and/or immunological markers which are site specific.

Microscopic: 5 = Cytology: Examination of cells whether from a primary or secondary site, including fluids aspirated using endoscopes or needles. Also including microscopic examination of peripheral blood films and trephine bone marrow aspirates; 6 = Histology of a metastases: Includes autopsy specimens; 7 = Histology of a primary tumour: Includes all cutting and bone marrow biopsies. Also includes autopsy specimens of a primary tumour; 9 = Unknown, e.g. PAS or HISS record only.

• MORPH_ICD10_O2, (Morphology of the cancer, in the ICD-10-O2 system)

• BEHAVIOUR_ICD10_O2 Behaviour of the cancer, in the ICD-10-O2 system

• STAGE_BEST, (where stage 1 is coded as 1, 1A, 1A2, 1B, 1C, 1E, 1S; stage 2 is coded as 2, 2A, 2A1, 2B, 2E, 2S; stage 3 is coded as 3, 3A, 3B, 3C, 3E, 3S; stage 4 is coded as 4, 4A, 4B, 4C, 4S; unknown or cannot be stage is coded as 4, 4A, 4B, 4C, 4S; unknown or cannot be staged as 0, 6, ?, U, X, blank)

• STAGE_PATH, (where stage 1 is coded as 1, 1A, 1B, 1E; stage 2 is coded as 2, 2A, 2B, 2E; stage 3 is coded as 3, 3A, 3B; stage 4 is coded as 4, 4A, 4B; unknown or cannot be staged as 0, 6, ?, X, blank)

• GRADE, (Grade of tumour, coded as 3, 4, G1, G2, G3, G4, G5, G6, G7, GX, Unknown or blank)

• CLARKS, (Clark's stage for skin cancer) 1 = melanoma in situ: melanoma cells are only in the epidermis; 2 = melanoma cells in the papillary dermis; 3 = melanoma cells throughout papillary dermis and touching reticula; 4 = melanoma has spread into the reticular or deep dermis; 5 = melanoma has grown into the subcutaneous fat.

• QUINTILE_2015, (Quintile score [1-5], describing income deprivation where 1= least deprived to 5= most deprived)

• DCO (Diagnosis of death certificate only coded as N=No, Y=Yes, blank)

Cancer registrations for lung cancer per 100,000 population. Directly standardised registration rate Source: Regional Cancer Registries, Office for National Statistics (ONS). Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2004-2006 Type of data: Administrative data